Holen Sie sich die Stockscreener-App
11.74
4.36%
0.49
Handel nachbörslich:
11.68
-0.06
-0.51%
Schlusskurs vom Vortag:
$11.25
Offen:
$11.38
24-Stunden-Volumen:
181.54K
Relative Volume:
1.52
Marktkapitalisierung:
$194.15M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-3.8492
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+19.67%
1M Leistung:
+10.65%
6M Leistung:
+22.29%
1J Leistung:
-35.07%
1-Tages-Spanne:
$11.00
$11.84
1-Wochen-Bereich:
$8.75
$11.84
52-Wochen-Spanne:
$5.6652
$26.56
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RAPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
11.74 | 186.05M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-09-14 | Eingeleitet | Berenberg | Buy |
| 2023-08-09 | Eingeleitet | Stifel | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Overweight |
| 2023-01-04 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-11-25 | Eingeleitet | UBS | Buy |
| 2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Will RAPT Therapeutics Inc. outperform tech stocksJuly 2025 Trends & Daily Risk Controlled Trade Plans - thegnnews.com
RAPT Therapeutics Inc. Recovery Likely Here’s What Data ShowsMarket Sentiment Review & Daily Price Action Insights - beatles.ru
How to forecast RAPT Therapeutics Inc. trends using time seriesWeekly Profit Analysis & Growth Focused Investment Plans - Newser
Understanding RAPT Therapeutics Inc.’s price movement2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - Newser
RAPT Therapeutics Inc. stock daily chart insightsMarket Volume Report & Low Drawdown Momentum Trade Ideas - Newser
Has RAPT Therapeutics Inc. formed a bullish divergenceTrade Ideas & Safe Capital Preservation Plans - Newser
RAPT Therapeutics Inc. Builds Base for Possible Rebound2025 Analyst Calls & Fast Entry High Yield Tips - beatles.ru
What high frequency data says about RAPT Therapeutics Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - Newser
Building trade automation scripts for RAPT Therapeutics Inc.2025 Market Overview & Smart Investment Allocation Insights - Newser
Sentiment analysis tools applied to RAPT Therapeutics Inc.Free Profit Target Stock Opportunity Monitor - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionLow Cost High Gain Picks - newsyoung.net
RAPT Therapeutics: UBS maintains Neutral, raises PT to $9 from $8. - AInvest
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance
Will RAPT Therapeutics Inc. continue its uptrendSector Rotation and Stock Opportunity Analysis - Newser
Volume spikes in RAPT Therapeutics Inc. stock – what they meanFree Smart Trade Plans With Risk Protection - Newser
Analyzing drawdowns of RAPT Therapeutics Inc. with statistical toolsAlgorithmic Forecast for Swing Trading Picks - Newser
Rapt Therapeutics (NASDAQ:RAPT) Cut to Sell at Wall Street Zen - Defense World
Historical volatility pattern of RAPT Therapeutics Inc. visualizedRisk Aware Trading Ideas with Alert Levels - Newser
HC Wainwright Issues Positive Forecast for RAPT Earnings - Defense World
Ranking RAPT Therapeutics Inc. among high performing stocks via toolsSmart Swing Picks with Confirmed Signals - Newser
Multi asset correlation models including RAPT Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Applying Elliott Wave Theory to RAPT Therapeutics Inc.Buy and Hold Position Summary Review - Newser
Published on: 2025-08-09 04:24:12 - beatles.ru
Using AI based signals to follow RAPT Therapeutics Inc.Stock Entry Point Planner with Volume Spike - Newser
Using Ichimoku Cloud for RAPT Therapeutics Inc. technicalsAlpha Stock Picks with Chart Confirmation - Newser
RAPT Therapeutics Reports Q2 2025 Financial Results: Net Loss of $34.8 Million, Cash and Securities Valued at $169 Million. - AInvest
Full technical analysis of RAPT Therapeutics Inc. stockAlpha Trade Flow With Risk Calibration - Newser
Rapt Therapeutics’ Reverse Stock Split: Potential Pitfalls and Market Challenges - TipRanks
Wells Fargo lowers Rapt Therapeutics stock price target to $38 on model changes - Investing.com Canada
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Cuts Target Price to $38 - 富途牛牛
RAPT Therapeutics Reports Q2 2025 Financial Results - TipRanks
RAPT Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
RAPT Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rapt Therapeutics reports Q2 EPS (65c), consensus (65c) - TipRanks
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Q2 net loss narrows to $17.6 mln, R&D expenses drop - MarketScreener
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):